SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-002129
Filing Date
2023-01-23
Accepted
2023-01-23 08:45:22
Documents
15
Period of Report
2023-01-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 51252
2 ex10-1.htm EX-10.1 84706
3 ex99-1.htm EX-99.1 35055
4 ex99-1_001.jpg GRAPHIC 5759
  Complete submission text file 0001493152-23-002129.txt   371139

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE rspi-20230118.xsd EX-101.SCH 3230
6 XBRL LABEL FILE rspi-20230118_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE rspi-20230118_pre.xml EX-101.PRE 22361
9 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3292
Mailing Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452
Business Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452 (201) 444-4947
RespireRx Pharmaceuticals Inc. (Filer) CIK: 0000849636 (see all company filings)

IRS No.: 330303583 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-16467 | Film No.: 23542619
SIC: 2834 Pharmaceutical Preparations